Novartis sues Teva for Jadenu patent infringement

Novartis has filed a complaint against Teva claiming the Israel-based company allegedly infringed one of its patents covering the drug Jadenu (deferasirox).

Jadenu, produced by Novartis, is an iron removal treatment for patients suffering with a chronic iron overload.

The case, filed in the US District Court for the District of Delaware, arose after Teva filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration for approval to market a generic version of the drug.

The ANDA was filed prior to the expiration of the patent in suit, US number 6,465,504.

Teva’s generic deferasirox tablets have the same active ingredient, dosage and strengths as Jadenu.

Novartis is demanding that the district court rules that its patent is valid, that the ANDA filed by Teva does not get approved before the expiration of the patent, and an order stopping Teva from selling the drug.

It is also demanding monetary relief if Teva decides to go through with the generic drug before the expiration date of the patent.